• LAST PRICE
    11.0800
  • TODAY'S CHANGE (%)
    Trending Up0.7100 (6.8467%)
  • Bid / Lots
    11.0000/ 1
  • Ask / Lots
    11.3000/ 1
  • Open / Previous Close
    10.3100 / 10.3700
  • Day Range
    Low 10.0200
    High 11.0800
  • 52 Week Range
    Low 4.9300
    High 31.3600
  • Volume
    19,918
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 10.37
TimeVolumeTYRA
09:32 ET31110.02
09:45 ET50010.2077
09:57 ET10010.365
10:03 ET40010.29
10:12 ET10010.32
10:15 ET10010.32
10:17 ET10010.41
11:36 ET100010.375
11:38 ET455210.33
11:42 ET30010.325
11:44 ET10010.24
11:45 ET20010.24
11:47 ET80010.24
12:03 ET10010.23
12:05 ET70010.49
12:41 ET100010.5
01:21 ET220010.495
01:32 ET10010.535
01:48 ET10010.44
01:55 ET40010.49
02:24 ET10010.59
02:38 ET15010.8189
03:14 ET10011.06
03:16 ET30011.05
03:23 ET10011.065
03:25 ET40011.08
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTYRA
Tyra Biosciences Inc
433.1M
-8.0x
---
United StatesGLUE
Monte Rosa Therapeutics Inc
432.6M
-4.1x
---
United StatesRGC
Regencell Bioscience Holdings Ltd
430.5M
-305.1x
---
United StatesOMER
Omeros Corp
428.4M
-2.2x
---
United StatesADGI
Adagio Therapeutics Inc
439.0M
-1.3x
---
United StatesHLVX
Hillevax Inc
423.9M
-2.5x
---
As of 2022-08-08

Company Information

Tyra Biosciences, Inc. is a precision oncology company. The Company is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The Company uses its SNAP platform, which enables refinement of structural design through iterative molecular SNAPshots. The Company is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family, which are altered in approximately 7% of all cancers. Its lead product candidate TYRA-300, an FGFR3 inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC). Its second product candidate, TYRA-200, is an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma (ICC). Its pipeline includes development programs targeting achondroplasia and other FGFR3-related skeletal dysplasias, REarranged during Transfection kinase (RET) and FGFR4-related cancers.

Contact Information

Headquarters
2656 State StreetCARLSBAD, CA, United States 92008
Phone
619-728-4760
Fax
302-655-5049

Executives

Non-Executive Chairman of the Board
Robert More
President, Chief Executive Officer, Treasurer, Director
Todd Harris
Chief Financial Officer
Esther Van Den Boom
Chief Operating Officer
Daniel Bensen
Chief Technology Officer
Robert Hudkins

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$433.1M
Revenue (TTM)
$0.00
Shares Outstanding
41.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.39
Book Value
$7.31
P/E Ratio
-8.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.